Skip to main content
NOXOPHARM LIMITED logo

NOXOPHARM LIMITED — Investor Relations & Filings

Ticker · NOX ISIN · AU000000NOX9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 786 across all filing types
Latest filing 2026-06-01 Director's Dealing
Country AU Australia
Listing ASX NOX

About NOXOPHARM LIMITED

https://www.noxopharm.com

Noxopharm Limited is a clinical-stage drug development company focused on the discovery and development of novel treatments for cancer and inflammation. The company utilizes its proprietary drug discovery platforms, including Chroma and Sofra, to create a pipeline of therapeutic candidates. Its lead oncology asset, Veyonda, is designed to function as a radio-enhancer and chemo-sensitizer, aiming to improve the efficacy of existing cancer treatments. Additionally, the Sofra platform focuses on the development of synthetic oligonucleotides to modulate the immune system, specifically targeting toll-like receptors 7 and 8 to treat autoimmune and inflammatory diseases. Noxopharm also explores applications in mRNA vaccine technology through its SOF-VAC program, which aims to reduce the inflammatory side effects associated with mRNA-based therapeutics.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 5.2KB
Director's Dealing Classification · 93% confidence The document is titled “Appendix 3Y – Change of Director's Interest Notice” under ASX listing rule 3.19A.2, detailing a director’s acquisition and disposal of securities and closed period queries. This is a director’s personal share transaction report (insider dealing), matching the Director’s Dealing category.
2026-06-01 English
New data confirms cancer-fighting potential 4 pages 482.5KB
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing new clinical and preclinical data on Noxopharm’s Sofra™ technology. There is no presentation attachment, no financials or earnings figures, no change of management, no regulatory certification, and it does not attach or publish a formal report. It reads as a generic ASX announcement/press release of R&D data, fitting the fallback Regulatory Filings category (RNS).
2026-05-25 English
Noxopharms Sofra assets to be presented at global conference 2 pages 374.8KB
Regulatory Filings Classification · 77% confidence The document is a press release announcing that Noxopharm’s Sofra assets will be presented at an upcoming global conference. It contains no financial statements, no earnings data, no management or board changes, no share issues, and is not a formal investor presentation or report. It is a general market announcement in compliance with regulatory disclosure requirements and does not fit any more specific category, making it a fallback Regulatory Filing (RNS).
2026-05-19 English
Proposed issue of securities - NOX 5 pages 19.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX announcement for the proposed issue of securities. It details the proposed placement of new securities (CEO options) as part of a remuneration package. The document includes specifics about the securities, issue date, and compliance with listing rules. It is not a full financial report, earnings release, or management discussion, but rather an announcement about a capital/financing activity related to share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not merely a brief notice or a report publication announcement, but a substantive announcement of a capital issue.
2026-05-07 English
Noxopharm progresses US regulatory strategy 3 pages 376.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing Noxopharm's progress in its US regulatory strategy, specifically preparations for a pre-IND meeting with the US FDA. It discusses strategic steps, engagement with a clinical research organization, and the potential commercial impact of the drug candidate SOF-SKN. There are no financial statements, detailed financial data, or comprehensive report content. The document is an update on regulatory and strategic progress rather than a formal regulatory filing or financial report. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory or corporate announcement category. Given the options, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2026-05-05 English
New data shows SOF-SKN active ingredient efficacy 4 pages 524.6KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing new research data on the efficacy of a drug candidate's active ingredient (SOF-16) in patient samples. It includes scientific study results, references to preprints and prior publications, and statements from the CEO about the progress and potential of the drug development. There are no financial statements, regulatory filings, voting results, or management changes. The document is not a formal financial report, earnings release, or regulatory filing. It is a corporate announcement focused on scientific and clinical progress, typical of a Capital/Financing Update or general corporate update. However, since it does not discuss fundraising, capital structure changes, or financing activities, it does not fit the Capital/Financing Update category. It is primarily a scientific and clinical update communicated to investors and the market. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2026-04-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.